Other new targets.
Despite improvements in surgical and diagnostic techniques, the outcome for women with advanced epithelial ovarian cancer remains poor. Recent developments in the understanding of cancer biology have led to an explosion in clinical trials using targeted agents. In women with epithelial ovarian cancer, antiangiogenic agents have led the field. There are, however, other novel targets and agents undergoing evaluation. This review focuses on some of these newer approaches to targeted therapy highlighting the importance of trial design and incorporation of biomarkers as we move forward into the era of personalized medicine.
Mackay
Helen J
HJ
Princess Margaret Hospital, University of Toronto, 610 University Ave., Toronto, Ontario, Canada. Helen.Mackay@uhn.on.ca
Oza
Amit M
AM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D016503:Drug Delivery Systems / Q000379:methods*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors